In short
This article explores the use of Metamizole Sodium Monohydrate in clinical trials, specifically focusing on its potential as a pain treatment for patients with chronic pancreatitis. The drug is being studied in a multicenter, randomized, double-blind, placebo-controlled trial to determine its effectiveness in reducing pain when added to current analgesic therapy. This research aims to improve the quality of life for individuals suffering from this painful condition.
At a glance
- Study Type
- Multicenter, randomized, double-blind, placebo-controlled trial
- Drug Studied
- Metamizole Sodium Monohydrate (Dolamizol 500 mg tablet)
- Condition
- Chronic pancreatitis
- Main Objective
- To reduce pain in chronic pancreatitis patients by adding metamizole to current analgesic therapy
- Dosage
- 1000mg three times daily
- Primary Outcome
- Mean daily pain intensity score over 4 weeks
- Secondary Outcomes
- Izbicki pain score, quality of life, patient satisfaction, pain-free days
- Inclusion Criteria
- Confirmed chronic pancreatitis, typical abdominal pain (NRS ≥ 3, ≥ 3 days/week for two weeks)
- Key Exclusion Criteria
- Recent interventions, high opioid use, active metamizole use, contraindications
What is Metamizole?
Metamizole sodium monohydrate, also known as dipyrone monohydrate, is a medication primarily used for pain relief. It belongs to a class of drugs called pyrazolones and is known for its pain-relieving (analgesic) and fever-reducing (antipyretic) properties. Metamizole is available in various forms, including tablets, and is being studied for its potential in managing chronic pain conditions.
Chronic Pancreatitis: An Overview
Chronic pancreatitis is a long-term inflammation of the pancreas, an organ that plays a crucial role in digestion and blood sugar regulation. One of the main symptoms of chronic pancreatitis is persistent abdominal pain, which can significantly impact a patient's quality of life. Managing this pain effectively is a key goal in treating chronic pancreatitis.
Clinical Trial on Metamizole for Chronic Pancreatitis Pain
A clinical trial is currently underway to investigate the effectiveness of metamizole in treating pain associated with chronic pancreatitis. The main objective of this study is to determine if adding metamizole to current pain management therapies can effectively reduce pain in patients who have been diagnosed with chronic pancreatitis within the last three years.
The study is designed as a multicenter, randomized, double-blind, placebo-controlled trial. This means:
- Multicenter: The study is conducted at multiple medical facilities.
- Randomized: Participants are randomly assigned to either receive metamizole or a placebo.
- Double-blind: Neither the patients nor the researchers know who is receiving metamizole or the placebo.
- Placebo-controlled: Some participants will receive a placebo (a substance with no active medication) to compare the effects with those receiving metamizole.
Who Can Participate in the Study?
The study has specific criteria for who can participate. These include:
Inclusion Criteria:
- Confirmed diagnosis of chronic pancreatitis
- Experiencing typical abdominal pain for chronic pancreatitis (dull pain in the upper abdomen) with a pain score of 3 or higher on a 0-10 scale, occurring at least 3 days a week for two weeks
Exclusion Criteria:
- Recent endoscopic or surgical intervention (within the last 3 months)
- Planned endoscopic or surgical intervention for chronic pancreatitis within the next 6 weeks
- Using high doses of opioid pain medications (more than 90 morphine milligram equivalents per day)
- Currently using metamizole
- Having any conditions that would make it unsafe to use metamizole
- Diagnosis of pancreatic cancer
- Recent start (less than 6 weeks ago) of certain medications like amitriptyline, pregabalin, or gabapentin
How is the Study Designed?
The study involves an intervention phase where all participants will receive either metamizole or a placebo in addition to their current pain management therapy. The key points of the study design are:
- Participants will be randomly assigned to either the metamizole group or the placebo group.
- The metamizole group will receive 1000mg of oral metamizole three times daily, in addition to their current pain medication.
- The placebo group will receive a placebo tablet three times daily, in addition to their current pain medication.
- The study will last for 6 weeks, with the intervention phase lasting 4 weeks.
How Will the Effectiveness be Measured?
The study will use several methods to measure how well metamizole works for pain relief:
- Primary measure: The main measure will be the average daily pain intensity score. Patients will record their pain levels daily using a scale from 0 (no pain) to 10 (worst pain imaginable).
- Secondary measures: These include:
- Izbicki pain score: A comprehensive pain assessment tool specific to pancreatic diseases
- The highest daily pain intensity score
- The number of patients achieving significant pain reduction
- The number of pain-free days
- The number of days with acceptable pain levels
- The total amount of additional pain medication (measured in morphine milligram equivalents) needed
- Quality of life assessments using standardized questionnaires (PANQOLI and SF-36)
- Patient satisfaction with the treatment (PGIC - Patient Global Impression of Change)
Potential Benefits and Considerations
If proven effective, metamizole could offer several benefits for patients with chronic pancreatitis:
- Improved pain management: It may provide better pain relief when added to current treatments.
- Reduced need for strong painkillers: It might help decrease the use of opioid medications, which can have significant side effects.
- Better quality of life: Effective pain management could lead to improved overall well-being and daily functioning.
However, it's important to note that this is still a research study, and the full effects and potential side effects of metamizole in this context are still being investigated. Patients should always consult with their healthcare providers before considering any new treatments or participating in clinical trials.